EU/3/02/099: Orphan designation for the treatment of oesophageal cancer


Table of contents


Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in November 2006 on request of the sponsor.

On 30 April 2002, orphan designation (EU/3/02/099) was granted by the European Commission to GPC Biotech AG, Germany, for bryostatin-1 for the treatment of oesophageal cancer.

Key facts

Active substance
Intended use
Treatment of oesophageal cancer
Orphan designation status
EU designation number
Date of designation
GPC Biotech AG
Fraunhoferstr. 20
D-82152 Martinsried/Munich
Telephone: +49 89 8565 3210
Telefax: +49 89 8565 3216

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating